Navigating the Malaysian Regulatory Landscape: An Interview with Melisa of TT Medical

1. Introduction: Market Access and Licensing in Malaysia

Teddy: Welcome to The Elendi Files, where we navigate the complexities of the global regulatory landscape of medical products. Our goal is to help make global medical product regulations accessible to everyone—whether you're a manufacturer, intermediary, regulatory specialist, or CEO of a med-tech startup. At ElendiLabs, we're all about connecting clients with the right regulatory expertise to get products to people faster. Today, I’m so thrilled to be joined by Melisa from TT Medical, a firm that helps navigate the complexities of the Malaysian market. Melisa, could you give us a brief introduction of what TT Medical specializes in?

Melisa: Hello, yes. Thank you for this opportunity to share insights into Malaysia registration. Basically, for TT Medical, we help companies legalize their medical devices and pharmaceutical products in Malaysia. We currently act as a license holder for medical devices, providing these services in Malaysia as well as in Indonesia.

2. Malaysia Class A Medical Device Registration: Timelines and Costs

Teddy: Let’s dive a bit deeper. What are the timelines and costs like for registering a Class A medical device in Malaysia?

Melisa: In Malaysia, classifications are broken into four categories: Class A, B, C, and D. Class A is equivalent to the EU Class 1. Based on recent progress, we foresee that even though it is a Class A device, a manufacturer needs to plan two months in advance. While the authority commits to about 30 working days, the real-world average approval timeline is currently about two to two and a half months.

Teddy: And what about the fees?

Melisa: The authority fee for Class A is currently 1,250 Ringgit, which is approximately $320 USD. This license is available for five years, after which you must pay the same fee for renewal. Regarding consultancy fees for license holding, for a Class A product registered for five years, it generally ranges from $1,000 to $1,500 USD, depending on how many products need to be registered. This is a one-off fee for five years, though there are additional charges from us and the authority if there are updates to documentation, labeling, IFUs, or the addition of new SKUs during the 5 year period.

3. The MDA Abridged Pathway: Using Reference Country Approvals

Teddy: Malaysia has a well-defined abridged pathway for devices already approved in other jurisdictions like the US, EU, or Australia. In 2026, what is the real-world timeline for an abridged Class B or C registration versus the official MDA target?

Melisa: To be entitled to the abridged pathway, the product must be registered in one of the reference countries. This reduces the third-party review of the technical file by a Conformity Assessment Body (CAB). A full review normally takes three to four months, but the abridged process can be completed in about one month before submission to the authority.

Teddy: So, a CAB review is a must for every class?

Melisa: It is mandatory for Class B, C, and D; Class A is not applicable for this third-party review. Not only is the abridged process faster, but it is also much cheaper. An abridged review fee is a maximum of $500 USD, whereas a full review starts from $2,000 USD onwards.

Teddy: Has the MDA recently expanded or tightened the list of recognized countries? How are they viewing UK MHRA or Singapore HSA approvals?

Melisa: The UK MHRA is definitely an eligible reference country. Last August, they added two more: Singapore and Thailand. If a product is already registered there, it is eligible for the abridged program, which uses terminology like the "verification route" versus the "full conformity route". However, having a reference country registration does not mean the technical documentation requirements are reduced. The file must still be in full compliance with Malaysian medical device regulations.

Teddy: Are you seeing major differences between the requirements of these reference countries and the local Malaysian authorities?

Melisa: Technical documentation requirements for Singapore, Thailand, Indonesia, and the Philippines are not significantly different; the ASEAN registration is largely in line with the European MDD requirements.

4. Selecting a Conformity Assessment Body (CAB) in Malaysia

Teddy: Some manufacturers might find it difficult to identify the right CAB. Do you have advice for choosing a third-party CAB that won't create a technical bottleneck?

Melisa: At TT Medical, we work with many CABs based on their schedule and pricing. For the verification route, we look primarily at their schedule. For a full conformity assessment, we have to look at the product's technical code, as not all CABs offer assessments for every specific scope. We often recommend a CAB based on their ability to deliver or their reasonable pricing, and we provide those summaries to the manufacturer for their decision-making.

Teddy: Are there any categories of devices where the MDA is allowing direct submission without a CAB to speed up market entry?

Melisa: Basically, only Class A products. Products for demos, research, or education do not require registration at all, though they require other approval processes.

5. Local Authorized Representatives (AR) and GDP MD Compliance

Teddy: For Class A devices, is it still compulsory to appoint a local Authorized Representative (AR)?

Melisa: Yes. And the AR must hold a valid establishment license. If a local partner fails a Good Distribution Practice for Medical Device (GDP MD) audit, the license could be suspended or revoked. Usually, the auditor will raise a non-conformity and give the company two or three months to rectify the issue before revoking the license.

"I have seen licenses revoked because an establishment never complied with regulations—for example, selling devices that were not registered. GDP MD audits are conducted on a yearly basis."

Teddy: Are these audits strict?

Melisa: I do not think they are overly strict if you maintain your system. Some companies fail because they use a standard template but are not "hands-on" and do not know how to maintain it. I have seen licenses revoked because an establishment never complied with regulations—for example, selling devices that were not registered. GDP MD audits are conducted on a yearly basis.

Teddy: Can these audits be conducted virtually?

Melisa: That was only allowed during the pandemic; now they must be physical, on-site inspections. The auditor must visit the company’s physical office, even if they don't have a warehouse, to verify records and check stock to ensure no unregistered products are being stored.

6. Regulating Drug-Device Combinations and Pharmaceuticals (NPRA)

Teddy: Regarding drug-device combinations, how do you determine if the gatekeeper is the MDA or the National Pharmaceutical Regulatory Agency (NPRA)?

Melisa: There are guidelines for determinations. For example, if a catheter has an antibiotic to prevent infection during surgery, it is a device-drug combination. It is regulated under the MDA, but we still submit the drug information to the Drug Control Authority for an endorsement letter to complete the registration.

Teddy: It seems very handy that TT Medical can handle both.

Melisa: Yes, in Malaysia, we can also be the "product holder" for pharmaceutical products. Drug registration is much longer, taking at least two to three years even for generics, while some new chemical entities can take up to four years. Conversely, products like cosmetics are regulated under the drug authority but only take about one month for registration.

Teddy: Thank you so much, Melisa. These are incredibly practical insights. We will be featuring TT Medical as a vetted specialist firm on the ElendiLabs platform. Thanks again for joining us, and we'll see you on the platform. If you haven't checked our website, please head to elendilabs.com and be sure to connect with us on LinkedIn.